Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Curr Pharm Des. 2010 May;16(14):1561-7. doi: 10.2174/138161210791164126.
The changes in beta-cell mass (BCM) during the course of diabetes are not yet well characterized. A non-invasive method to measure the BCM in vivo would allow us to study the BCM during the onset and progression of the diseases caused by beta-cell dysfunction. PET and SPECT imaging are attractive approaches to determine the BCM because of their high sensitivity and the possibility to quantitatively analyze the images. Several targets and their corresponding radiotracers have been examined for their ability to determine the BCM including radiolabeled antibodies, antibody fragments, peptides and small molecules. Although some of these tracers show promising results, there is still no reliable method to determine the beta-cell mass in vivo. In this review, the targets and the corresponding radiotracers evaluated so far for the determination of the BCM in vivo in humans will be discussed.
β细胞质量（BCM）在糖尿病病程中的变化尚不清楚。一种非侵入性的活体测量 BCM 的方法，将使我们能够在β细胞功能障碍引起的疾病的发生和进展过程中研究 BCM。正电子发射断层扫描（PET）和单光子发射计算机断层扫描（SPECT）成像是确定 BCM 的有吸引力的方法，因为它们具有高灵敏度和对图像进行定量分析的可能性。已经研究了几种靶标及其相应的放射性示踪剂来确定 BCM，包括放射性标记的抗体、抗体片段、肽和小分子。尽管其中一些示踪剂显示出有前途的结果，但仍然没有可靠的方法来确定活体的β细胞质量。在这篇综述中，将讨论迄今为止为在人体中活体确定 BCM 而评估的靶标和相应的放射性示踪剂。
